FXR activation normalizes insulin sensitivity in visceral preadipocytes of a rabbit model of mets

Journal of Endocrinology

Volumn 218, Issue 2, 2013, Pages 215-231

  Maneschi, Elena ^a   Vignozzi, Linda ^a   Morelli, Annamaria ^a   Mello, Tommaso ^a   Filippi, Sandra ^b   Cellai, Ilaria ^a   Comeglio, Paolo ^a   Sarchielli, Erica ^a   Calcagno, Alessandra ^c   Mazzanti, Benedetta ^a   Vettor, Roberto ^c   Vannelli, Gabriella Barbara ^a   Adorini, Luciano ^d   Maggi, Mario ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d INTERCEPT PHARMACEUTICALS   (United States)

Author keywords

adipogenesis; glucose transport; insulin signaling; lipid droplet; liver; preadipocytes; steatohepatitis

Indexed keywords

FARNESOID X RECEPTOR; FAT DROPLET; GLUCOSE TRANSPORTER 4; INSULIN; OBETICHOLIC ACID; PERILIPIN; TRIACYLGLYCEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL SIZE; CONTROLLED STUDY; EXPERIMENTAL RABBIT; GLUCOSE TRANSPORT; HYPOXIA; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INSULIN SENSITIVITY; LIPOGENESIS; METABOLIC SYNDROME X; NONHUMAN; PRIORITY JOURNAL; PROADIPOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADIPOCYTES; ANIMALS; HUMANS; INSULIN; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; LIVER; MALE; METABOLIC SYNDROME X; RABBITS; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 84880661849     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-13-0109     Document Type: Article

References (54)

1. Adorini L, Pruzanski M & Shapiro D 2012 Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discovery Today 17 988-997 (Review). (doi:10.1016/j.drudis.2012.05.012)
2. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr et al. 2009 Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120 1640-1645. (doi:10.1161/CIRCULATIONAHA.109.192644)
3. Boström P, Andersson L, Rutberg M, Perman J, Lidberg U, Johansson BR, Fernandez-Rodriguez J, Ericson J, Nilsson T, Borén J et al. 2007 SNARE proteins mediate fusion between cytosolic lipid droplets and are implicated in insulin sensitivity. Nature Cell Biology 9 1286-1293. (doi:10.1038/ncb1648)
4. Brasaemle DL 2007 Thematic review series: adipocyte biology. The perilipin family of structural lipid droplet proteins: stabilization of lipid droplets and control of lipolysis. Journal of Lipid Research 48 2547-2559. (doi:10.1194/jlr. R700014-JLR200)
5. Cariou B, van Harmelen K, Duran-Sandoval D, van Dijk TH, Grefhorst A, Abdelkarim M, Caron S, Torpier G, Fruchart JC, Gonzalez FJ et al. 2006 The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. Journal of Biological Chemistry 281 11039-11049. (doi:10.1074/jbc. M510258200)
6. Cipriani S, Mencarelli A, Palladino G & Fiorucci S 2010 FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. Journal of Lipid Research 51 771-784. (doi:10.1194/jlr. M001602)
7. Cusi K 2012 Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology 142 711-725.e6. (doi:10.1053/j.gastro.2012. 02.003)
8. De Lean A, Munson PJ & Rodbard D 1978 Simultaneous analysis of familiesof sigmoidal curves: applications to biossay, radioligand assay, and physiological dose-response curves. American Journal of Physiology 235 97-102.
9. Després JP & Lemieux I 2006 Abdominal obesity and metabolic syndrome. Nature 444 881-887. (doi:10.1038/nature05488)
10. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD & Parks EJ 2005 Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. Journal of Clinical Investigation 115 1343-1351. (doi:10.1172/JCI 200523621)
11. Farrell GC 2009 The liver and the waistline: fifty years of growth. Journal of Gastroenterology and Hepatology 24 S105-S118. (doi:10.1111/j.1440-1746.2009.06080.x)
12. Filippi S, Vignozzi L, Morelli A, Chavalmane AK, Sarchielli E, Fibbi B, Saad F, Sandner P, Ruggiano P, Vannelli GB et al. 2009 Testosterone partially ameliorates metabolic profile and erectile responsiveness to PDE5 inhibitors in an animal model of male metabolic syndrome. Journal of Sexual Medicine 6 3274-3288. (doi:10.1111/j.1743-6109.2009.01467.x)
13. Fiorucci S, Cipriani S, Baldelli F & Mencarelli A 2010 Bile acid-activated receptors in the treatment of dyslipidemia and related disorders. Progress in Lipid Research 49 171-185. (doi:10.1016/j.plipres. 2009.11.001)
14. Foster LJ, Yaworsky K, Trimble WS & Klip A 1999 SNAP23 promotes insulindependent glucose uptake in 3T3-L1 adipocytes: possible interaction with cytoskeleton. American Journal of Physiology 276 C1108-C1114.
15. Franck N, Stenkula KG, Ost A, Lindström T, Strålfors P & Nystrom FH 2007 Insulin-induced GLUT4 translocation to the plasma membrane is blunted in large compared with small primary fat cells isolated from the same individual. Diabetologia 50 1716-1722. (doi:10.1007/s00125-007-0713-1)
16. Fu M, Wang C, Li Z, Sakamaki T & Pestell RG 2004 Minireview: cyclin D1: normal and abnormal functions. Endocrinology 145 5439-5447 (Review). (doi:10.1210/en.2004-0959)
17. Goossens GH 2007 The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance. Physiology & Behavior 94 206-218. (doi:10.1016/j.physbeh.2007.10.010)
18. Gustafson B, Gogg S, Hedjazifar S, Jenndahl L, Hammarstedt A & Smith U 2009 Inflammation and impaired adipogenesis in hypertrophic obesity in man. American Journal of Physiology. Endocrinology and Metabolism 297 E999-E1003 (Review). (doi:10.1152/ajpendo.00377.2009)
19. Jacobsson B & Smith U 1972 Effect of cell size on lipolysis and antilipolytic action of insulin in human fat cells. Journal of Lipid Research 13 651-656.
20. Kawanishi M, Tamori Y, Okazawa H, Araki S, Shinoda H & Kasuga M 2000 Role of SNAP23 in insulin-induced translocation of GLUT4 in 3T3-L1 adipocytes. Mediation of complex formation between syntaxin4 and VAMP2. Journal of Biological Chemistry 275 8240-8247. (doi:10.1074/jbc.275.11.8240)
21. Larter CZ, Chitturi S, Heydet D & Farrell GC 2010 A fresh look at NASH pathogenesis. Part 1: the metabolic movers. Journal of Gastroenterology and Hepatology 25 672-690. (doi:10.1111/j.1440-1746.2010.06253.x)
22. Laurencikiene J, Skurk T, Kulyté A, Hedén P, Aström G, Sjölin E, Rydén M, Hauner H & Arner P 2011 Regulation of lipolysis in small and large fat cells of the same subject. Journal of Clinical Endocrinology and Metabolism 12 E2045-E2049. (doi:10.1210/jc.2011-1702)
23. Ma K, Saha PK, Chan L & Moore DD 2006 Farnesoid X receptor is essential for normal glucose homeostasis. Journal of Clinical Investigation 116 1102-1109. (doi:10.1172/JCI25604)
24. Maneschi E, Morelli A, Filippi S, Cellai I, Comeglio P, Mazzanti B, Mello T, Calcagno A, Sarchielli E, Vignozzi L et al. 2012 Testosterone treatment improves metabolic syndrome-induced adipose tissue derangements. Journal of Endocrinology 215 347-362. (doi:10.1530/JOE-12-0333)
25. Morelli A, Comeglio P, Filippi S, Sarchielli E, Cellai I, Vignozzi L, Yehiely-Cohen R, Maneschi E, Gacci M, Carini M et al. 2012 Testosterone and farnesoid X receptor agonist INT-747 counteract high fat diet-induced bladder alterations in a rabbit model of metabolic syndrome. Journal of Steroid Biochemistry and Molecular Biology 132 80-92. (doi:10.1016/j.jsbmb.2012.02.007)
26. Morelli A, Comeglio P, Filippi S, Sarchielli E, Vignozzi L, Maneschi E, Cellai I, Gacci M, Lenzi A, Vannelli GB et al. 2013 Mechanism of action of phosphodiesterase type 5 inhibition in metabolic syndromeassociated prostate alterations: an experimental study in the rabbit. Prostate 73 428-441. (doi:10.1002/pros.22584)
27. Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, Kipnes M, Adorini L, Sciacca CI, Clopton P, Castelloe E et al. 2013 Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology In press. (doi:10.1053/j.gastro.2013.05.042)
28. Olefsky JM 1976 The effects of spontaneous obesity on insulin binding, glucose transport, and glucose oxidation of isolated rat adipocytes. Journal of Clinical Investigation 57 842-851. (doi:10.1172/JCI108360)
29. O'Rourke RW, White AE, Metcalf MD, Olivas AS, Mitra P, Larison WG, Cheang EC, Varlamov O, Corless CL, Roberts CT Jr et al. 2011 Hypoxiainduced inflammatory cytokine secretion in human adipose tissue stromovascular cells. Diabetologia 54 1480-1490. (doi:10.1007/s00125-011-2103-y)
30. Pellicciari R, Fiorucci S, Camaioni E, Clerici C, Costantino G, Maloney PR, Morelli A, Parks DJ & Willson TM 2002 6a-Ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. Journal of Medicinal Chemistry 45 3569-3572. (doi:10.1021/jm025529g)
31. Pellicciari R, Gioiello A, Macchiarulo A, Thomas C, Rosatelli E, Natalini B, Sardella R, Pruzanski M, Roda A, Pastorini E et al. 2009 Discovery of 6a-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity. Journal of Medicinal Chemistry 52 7958-7961. (doi:10.1021/jm901390p)
32. Renga B, Mencarelli A, Vavassori P, Brancaleone V & Fiorucci S 2010 The bile acid sensor FXR regulates insulin transcription and secretion. Biochimica et Biophysica Acta 1802 363-372. (doi:10.1016/j.bbadis. 2010.01.002)
33. Rizzo G, Disante M, Mencarelli A, Renga B, Gioiello A, Pellicciari R & Fiorucci S 2006 The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo. Molecular Pharmacology 70 1164-1173. (doi:10.1124/mol.106.023820)
34. Rizzo G, Passeri D, De Franco F, Ciaccioli G, Donadio L, Rizzo G, Orlandi S, Sadeghpour B, Wang XX, Jiang T et al. 2010 Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist. Molecular Pharmacology 78 617-630. (doi:10.1124/mol.110.064501)
35. Salans LB & Dougherty JW 1971 The effect of insulin upon glucose metabolism by adipose cells of different size. Influence of cell lipid and protein content, age, and nutritional state. Journal of Clinical Investigation 50 1399-1410. (doi:10.1172/JCI106623)
36. Salans LB, Knittle JL & Hirsch J 1968 The role of adipose cell size and adipose tissue insulin sensitivity in the carbohydrate intolerance of human obesity. Journal of Clinical Investigation 47 153-165. (doi:10.1172/JCI105705)
37. Salans LB, Bray GA, Cushman SW, Danforth E Jr, Glennon JA, Horton ES & Sims EA 1974 Glucose metabolism and the response to insulin by human adipose tissue in spontaneous and experimental obesity. Effects of dietary composition and adipose cell size. Journal of Clinical Investigation 53 848-856. (doi:10.1172/JCI107625)
38. Samocha-Bonet D, Chisholm DJ, Tonks K, Campbell LV & Greenfield JR 2012 Insulin-sensitive obesity in humans-a 'favorable fat' phenotype? Trends in Endocrinology and Metabolism 23 116-124. (doi:10.1016/j.tem. 2011.12.005)
39. Sarruf DA, Iankova I, Abella A, Assou S, Miard S & Fajas L 2005 Cyclin D3 promotes adipogenesis through activation of peroxisome proliferatoractivated receptor g. Molecular and Cellular Biology 25 9985-9995. (doi:10.1128/MCB.25.22.9985-9995.2005)
40. Sato H, Genet C, Strehle A, Thomas C, Lobstein A, Wagner A, Mioskowski C, Auwerx J & Saladin R 2007 Anti-hyperglycemic activity of a TGR5 agonist isolated from Olea europaea. Biochemical and Biophysical Research Communications 362 793-798. (doi:10.1016/j.bbrc.2007.06.130)
41. Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G & Gonzalez F 2000 Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 102 731-744. (doi:10.1016/S0092-8674(00)00062-3)
42. Smith U 1971 Effect of cell size on lipid synthesis by human adipose tissue in vitro. Journal of Lipid Research 12 65-70.
43. Smith CE & Ordovás JM 2012 Update on perilipin polymorphisms and obesity. Nutrition Reviews 70 611-621 (Review). (doi:10.1111/j.1753-4887.2012.00515.x)
44. Snel M, Jonker JT, Schoones J, Lamb H, de Roos A, Pijl H, Smit JW, Meinders AE & Jazet IM 2012 Ectopic fat and insulin resistance: pathophysiology and effect of diet and lifestyle interventions. International Journal of Endocrinology 2012 983814. (doi:10.1155/2012/983814)
45. Student AK, Hsu RY & Lane MD 1980 Induction of fatty acid synthetase synthesis in differentiating 3T3-L1 preadipocytes. Journal of Biological Chemistry 255 4745-4750.
46. Targher G & Byrne CD 2013 Clinical review: nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. Journal of Clinical Endocrinology and Metabolism 98 483-495. (doi:10.1210/jc.2012-3093)
47. Thomas C, Pellicciari R, Pruzanski M, Auwerx J & Schoonjans K 2008 Targeting bile-acid signalling for metabolic diseases. Nature Reviews. Drug Discovery 7 678-693 (Review). (doi:10.1038/nrd2619)
48. Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, Macchiarulo A, Yamamoto H, Mataki C, Pruzanski M et al. 2009 TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metabolism 10 167-177. (doi:10.1016/j.cmet.2009.08.001)
49. Timmons JA, Wennmalm K, Larsson O, Walden TB, Lassmann T, Petrovic N, Hamilton DL, Gimeno RE, Wahlestedt C, Baar K et al. 2007 Myogenic gene expression signature establishes that brown and white adipocytes originate from distinct cell lineages. PNAS 104 4401-4406. (doi:10.1073/pnas.0610615104)
50. Trayhurn P 2013 Hypoxia and adipose tissue function and dysfunction in obesity. Physiological Reviews 93 1-21. (doi:10.1152/physrev.00017.2012)
51. Vignozzi L, Morelli A, Filippi S, Comeglio P, Chavalmane AK, Marchetta M, Toce M, Yehiely-Cohen R, Vannelli GB, Adorini L et al. 2011 Farnesoid X receptor activation improves erectile function in animal models of metabolic syndrome and diabetes. Journal of Sexual Medicine 8 57-77. (doi:10.1111/j.1743-6109.2010.02073.x)
52. Vignozzi L, Morelli A, Sarchielli E, Comeglio P, Filippi S, Cellai I, Maneschi E, Serni S, Gacci M, Carini M, et al. 2012 Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit. Journal of Endocrinology 212 71-84. (doi:10.1530/JOE-11-0289)
53. Virtue S & Vidal-Puig A 2010 Adipose tissue expandability, lipotoxicity and the metabolic syndrome-an allostatic perspective. Biochimica et Biophysica Acta 1801 338-349 (Review). (doi:10.1016/j.bbalip.2009.12.006)
54. Zhang Y, Lee FY, Barrera G, Lee H, Vales C, Gonzalez FJ, Willson TM & Edwards PA 2006 Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. PNAS 103 1006-1011. (doi:10.1073/pnas.0506982103)